-- MCT-125 for the treatment of primary fatigue in MS patients.
-- MCT-175 for the treatment of relapsing-remitting MS.
-- MCT-465 for the treatment of TLR3 positive breast cancers.
-- MCT-475 for the treatment of TLR3 positive cervical cancers.
For more information about MultiCell Technologies, please visit http://www.multicelltech.com
Caution Regarding Forward-Looking Statements
Any statements in this press release about MultiCell's expectations,
beliefs, plans, objectives, assumptions or future events or performance are
not historical facts and are forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). These
statements are often, but not always, made through the use of words or
phrases such as "believe," "will," "expect," "anticipate," "estimate,"
"intend," "plan," "forecast," "could," and "would." Examples of such
forward looking statements include statements regarding the timing, design,
scope, and anticipated results of our clinical development of MCT-125,
statements regarding selling, using or developing the FA2N-4 cell line and
MultiCell's identification of new drug targets. MultiCell bases these
forward-looking statements on current expectations about future events.
They involve known and unknown risks, uncertainties and assumptions that
may cause actual results, levels of activity, performance or achievements
to differ materially from those expressed or implied by any forward-looking
statement. Some of the risks, uncertainties and assumptions that could
cause actual results to differ materially from estimates or projections in
the forward-looking statement include, but are not limited to, the risk
that we might not achieve our anticipated clinical development milestones,
|SOURCE MultiCell Technologies, Inc.|
Copyright©2007 PR Newswire.
All rights reserved